IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of HABERMANN, et al. Examiner:

STEADMAN, David J.

Art Unit:

1652

Application No.: 10/076,632

Filed: February 19, 2002

Title: NUCLEIC ACIDS ENCODING HIRUDIN

FUSION PROTEINS AND METHODS FOR PRODUCING HIRUDIN FUSION

PROTEINS [AMENDED TITLE]

thereby certify that this correspondence is being eposited with the United States Postal Service as it Class Mail in an envelope addressed to ommissioner for Patents, P.O. Box 1450, exandria, VA 22313-1450, on

October 28, 2004

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

DEAV2001/0009 US NP Serial No.: 10/076,634

\boxtimes	(b)	This Information Disclosure Statement is filed after the period set forth in 37						
		C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action						
		under §1.113 or a notice of allowance under §1.311, whichever occurs first.						
		(1)	The undersigned attorney certifies that each item of information contained					
			in this Information Disclosure Statement was cited in a communication					
			from a foreign patent office in a counterpart foreign application not more					
			than three months prior to the filing of this statement;					
		(2)	The undersigned attorney certifies that no item of information contained in					
			this Information Disclosure Statement was cited in a communication from a					
			foreign patent office in a counterpart foreign application or, to the					
			knowledge of the undersigned attorney after making reasonable inquiry,					
			was known to any individual designated in §1.56(c) more than three					
			months prior to the filing of this statement; or					
	\boxtimes	(3)	This Information Disclosure Statement is accompanied by a transmittal					
			letter in which payment of the fee set forth in §1.17(p) and required by 37					
			C.F.R. 1.97(c) is authorized.					

In the Office Action dated May 20, 2004, the Examiner indicated that he did not consider DE 100 33 195 A1 and DE 34 30 556 A1, because these references were not present in the application. The Applicants submit that information now.

German Patent Application No. 100 33 195 corresponds to US Patent Application Publication No. US2002/173620 A1, which the Applicants have attached to this paper.

As to German Patent Application No. 34 30 556, the Applicants provide the following translation of its abstract:

The invention relates to a process for purifying dimethyl terephthalate (DMT). A DMT-containing mixture is used whose DMT content is above the DMT content of the eutectic composition. The DMT-containing mixture is melted and the DMT is allowed to crystallise out by cooling, but without the DMT content in the impurities reaching the eutectic composition.

Respectfully submitted,

Joel B. German, Reg. No., 48,676 Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3444
Telefax (908) 231-2626
Aventis Docket No. DEAV2001/0008 US NP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of HABERMANN, et al. Examiner:

Art Unit:

STEADMAN, David J.

Application No.: 10/076,632

1652

Filed: February 19, 2002

Title: NUCLEIC ACIDS ENCODING HIRUDIN FUSION PROTEINS AND METHODS FOR PRODUCING HIRUDIN FUSION PROTEINS [AMENDED TITLE]

Certificate of Mailing or Transmission

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop address below, or being facsimile transmitted to the USPTO, on the date indicated below.

October 28, 2004 Date of Deposit

Printed Name rson Signing Certificate Jonas Pierre, Sr.

Signature

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT FOR WHICH THE FEE SPECIFIED UNDER 37 C.F.R. 1.97(c) IS REQUIRED

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Enclosed is an Information Disclosure Statement for which the fee specified in 37 C.F.R. 1.97(c) is required.

Please charge Deposit Account No. 18-1982 in the amount of \$180.00. Two duplicate copies of this sheet are enclosed. The Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

Respectfully submitted,

Joel B. German, Reg. No., 48,676 Aptorney/Agent for Applicant

Aventis Pharmaceuticals Inc. Patent Department Route #202-206 / P.O. Box 6800 Bridgewater, NJ 08807-0800 Telephone (908) 231-3444 Telefax (908) 231-2626

Aventis Docket No. DEAV2001/0008 US NP

Please type a plus sign (+) inside this box →		
---	--	--

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	•
-------	---	----	---

Complete if Known					
Application Number	10/076,632				
Filing Date	02-19-2002				
First Named Inventor	HABERMANN, et al.				
Group Art Unit	1652				
Examiner Name	STEADMAN, David J.				
Attorney Docket Number	DEAV2001/0008 - US - NP	_			

	U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	U.S. Patent Document Kind Code ² (if known)		Name of Patentee or Applicant	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
		09/899,235		HABERMANN	07-06-2001	1.44			
1			THE B						
					<u> </u>				
		<u> </u>							

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*		Foreign Patent Document				Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant		
		Office ³	Number ⁴	Kind Cod (if know		Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T6	
						•		 .		
									Ш	
		\sqcup			4	<u> </u>			Ш	
					4				Ш	

Examiner		Date	
Signature	*	Considered	L

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.